SUDEEPPHRM Sudeep Pharma Q3 FY26 results (Oct–Dec 2025) and concall
Sudeep Pharma reported a strong Q3 FY26, with total income growing 52% YoY to INR 179.2 crores and PAT increasing 66% YoY to INR 47.7 crores. The company's EBITDA margin stood at 37.3%. Growth was driven by robust demand, strategic investments, and strong performance in the specialty ingredients segment. Key projects like the Dahej Battery Materials Facility and Nandesari Greenfield facility are progressing as planned, positioning the company for future growth and market diversification.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 8.4%, net profit up 28.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 149 | 83 | 105 | 80 | 88 −41% | 90 +8% |
| EBITDA | 63 | 26 | 45 | 30 | 31 −51% | 30 +15% |
| Net profit | 49 | 21 | 33 | 25 | 30 −39% | 27 +29% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
